The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Co, M. S.
Right arrow Articles by Hudson, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Co, M. S.
Right arrow Articles by Hudson, D.

The Journal of Immunology, Vol 152, Issue 6 2968-2976, Copyright © 1994 by American Association of Immunologists


ARTICLES

A humanized antibody specific for the platelet integrin gpIIb/IIIa

MS Co, S Yano, RK Hsu, NF Landolfi, M Vasquez, M Cole, JT Tso, T Bringman, W Laird and D Hudson
Protein Design Labs, Inc., Mountain View, CA 94043.

C4G1, a murine mAb reactive with the platelet gpIIb/IIIa integrin, was humanized for potential treatment of thrombosis-related disorders. The variable regions of light- and heavy-chain cDNAs from the C4G1 hybridoma were first cloned and sequenced. Humanized C4G1 Ab of the IgG1 isotype was constructed by combining the complementarity- determining regions of C4G1 with human framework and constant regions. The human framework was chosen to maximize homology with the C4G1 variable region sequence, and a computer model of C4G1 was used to aid design of the final framework sequence. Genetic constructs were also developed to produce Fab and F(ab')2 fragments of the humanized C4G1 Ab. The humanized IgG1 Ab as well as the Fab and F(ab')2 fragments showed equivalent binding affinities to their murine counterparts, indicating no loss in binding affinity during the humanization process. The humanized Ab and its fragments were also shown to inhibit platelet aggregation and to inhibit binding of fibrinogen to gpIIb/IIIa in vitro.


This article has been cited by other articles:


Home page
J. Immunol.Home page
M.-J. Jacobin, J. Laroche-Traineau, M. Little, A. Keller, K. Peter, M. Welschof, A. Nurden, and G. Clofent-Sanchez
Human IgG Monoclonal Anti-{alpha}IIb{beta}3-Binding Fragments Derived from Immunized Donors Using Phage Display
J. Immunol., February 15, 2002; 168(4): 2035 - 2045.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
X.-Y. He, Z. Xu, J. Melrose, A. Mullowney, M. Vasquez, C. Queen, V. Vexler, C. Klingbeil, M. S. Co, and E. L. Berg
Humanization and Pharmacokinetics of a Monoclonal Antibody with Specificity for Both E- and P-Selectin
J. Immunol., January 15, 1998; 160(2): 1029 - 1035.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1994 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1994 by The American Association of Immunologists, Inc. All rights reserved.